Evidence map›Paper›PMID 20603440›Full record

GuidelineAnnals of oncology : official journal of the European Society for Medical Oncology2011

International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.

S Dawood, S D Merajver, P Viens, P B Vermeulen, S M Swain, T A Buchholz, L Y Dirix, P H Levine, A Lucci, S Krishnamurthy and 5 more

Registry-linked trialAbstract readConsensus StatementPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Annals of oncology : official journal of the European Society for Medical Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03515798 (A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer.), which is not on this map. Cited by 205 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
205citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03515798 phase2active not recruitingnot on this mapstarted 2018, after this paper: background citation

A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer.

TypeinterventionalSponsorInstitut Paoli-CalmettesRan2018 to 2027Enrolled52ConditionsInflammatory Breast CancerArmsPembrolizumab Injection, neoadjuvant EC-paclitaxel chemotherapy
3 · Its place in the literature

Who cites it

205 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Shared decision making in breast cancer treatment guidelines: Development of a quality assessment tool and a systematic review.Health expectations : an international journal of public participation in health care and health policy · 2020
    Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

145 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

S DawoodDepartment of Medical Oncology, Dubai Hospital, Department of Health and Medical Services, Dubai, United Arab Emirates.
S D MerajverDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
P ViensDepartment of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
P B VermeulenDepartment of Pathology, General Hospital Sint-Augustinus, Antwerp, Belgium.
S M SwainWashington Cancer Institute, Washington Hospital Center, Washington, DC, USA.
T A BuchholzDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
L Y DirixTranslational Cancer Research Group Antwerp, General Hospital Sint-Augustinus, Antwerp, Belgium.
P H LevineDepartment of Epidemiology and Biostatistics, School of Public Health and Health Services, George Washington University, Washington, DC.
A LucciDepartment of Surgical Oncology.
S KrishnamurthyDepartment of Pathology.
F M RobertsonDepartment of Experimental Therapeutics.
W A WoodwardDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
W T YangDepartment of Diagnostic Radiology.
N T UenoDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
M CristofanilliDepartment of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: Massimo.Cristofanilli@fccc.edu.

Funding

PHS HHS 1R13 00451843
6 · The paper itself

Abstract

backgroundInflammatory breast cancer (IBC) represents the most aggressive presentation of breast cancer. Women diagnosed with IBC typically have a poorer prognosis compared with those diagnosed with non-IBC tumors. Recommendations and guidelines published to date on the diagnosis, management, and follow-up of women with breast cancer have focused primarily on non-IBC tumors. Establishing a minimum standard for clinical diagnosis and treatment of IBC is needed.

methodsRecognizing IBC to be a distinct entity, a group of international experts met in December 2008 at the First International Conference on Inflammatory Breast Cancer to develop guidelines for the management of IBC.

resultsThe panel of leading IBC experts formed a consensus on the minimum requirements to accurately diagnose IBC, supported by pathological confirmation. In addition, the panel emphasized a multimodality approach of systemic chemotherapy, surgery, and radiation therapy.

conclusionsThe goal of these guidelines, based on an expert consensus after careful review of published data, is to help the clinical diagnosis of this rare disease and to standardize management of IBC among treating physicians in both the academic and community settings.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAromatase InhibitorsBiomarkers, TumorDiagnostic Techniques and ProceduresErb-b2 Receptor Tyrosine KinasesFemaleHumansInflammatory Breast NeoplasmsNeoadjuvant TherapyNeoplasm InvasivenessNeoplasm MetastasisNeoplasm StagingRadiotherapy, AdjuvantReceptors, EstrogenAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAromatase InhibitorsBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneTamoxifenTrastuzumab

Identifiers

PMID20603440
PMCPMC3105293

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.